Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1971 Jan 30;1(5743):267–268. doi: 10.1136/bmj.1.5743.267

Incidence of Side Effects from Levodopa during the Introduction of Treatment

R B Godwin-Austen, C C Frears, S Bergmann
PMCID: PMC1794966  PMID: 5100498

Abstract

Twenty patients with Parkinsonism were investigated in order to establish whether the gradual introduction of treatment with levodopa allows a higher dose to be tolerated than can be achieved if treatment is introduced rapidly. No indication was obtained that slow introduction of treatment offers an advantage in maximum tolerated dose, and patients aged 65 and over responded similarly in this respect to those under 65. The maximum tolerated dose is slightly lower in the elderly patient. The incidence of the different side effects does not appear to be affected by the rate of increasing the dose of levodopa.

Full text

PDF
267

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calne D. B., Brennan J., Spiers A. S., Stern G. M. Hypotension caused by L-dopa. Br Med J. 1970 Feb 21;1(5694):474–475. doi: 10.1136/bmj.1.5694.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calne D. B., Stern G. M., Laurence D. R., Sharkey J., Armitage P. L-dopa in postencephalitic parkinsonism. Lancet. 1969 Apr 12;1(7598):744–746. doi: 10.1016/s0140-6736(69)91751-6. [DOI] [PubMed] [Google Scholar]
  3. Calne D. B., Stern G. M., Spiers A. S., Laurence D. R. L-dopa in idiopathic parkinsonism. Lancet. 1969 Nov 8;2(7628):973–976. doi: 10.1016/s0140-6736(69)90536-4. [DOI] [PubMed] [Google Scholar]
  4. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  5. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  6. Godwin-Austen R. B., Lind N. A., Turner P. Mydriatic responses to sympathomimetic amines in patients treated with L-dopa. Lancet. 1969 Nov 15;2(7629):1043–1044. doi: 10.1016/s0140-6736(69)90646-1. [DOI] [PubMed] [Google Scholar]
  7. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  8. Klawans H. L., Jr, Garvin J. S. Treatment of parkinsonism with L-dopa (study of 105 patients). Dis Nerv Syst. 1969 Nov;30(11):737–746. [PubMed] [Google Scholar]
  9. Spiers A. S., Calne D. B., Fayers P. M. Miosis during L-dopa therapy. Br Med J. 1970 Jun 13;2(5710):639–640. doi: 10.1136/bmj.2.5710.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Yahr M. D., Duvoisin R. C., Hoehn M. M., Schear M. J., Barrett R. E. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Trans Am Neurol Assoc. 1968;93:56–63. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES